EUVIMEDEUVIMED entdecken
Crossref

A simple procedure to identify children with B‐lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single‐point minimal residual disease measurement

Alexander Popov iD, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Mikhail Belevtsev, Tatiana Verzhbitskaya, Elena Boyakova, Liudmila Movchan, Grigory Tsaur iD, Maria Fadeeva, Svetlana Lagoyko, Liudmila Zharikova und 10 weitere

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Alexander Popov und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sequential monitoring of minimal residual disease (MRD) by molecular techniques or multicolor flow cytometry (MFC) has emerged over the past two decades as the primary tool to optimize treatment in pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). The aim of our study was to compare the prognostic power of repeated MFC–MRD measurement with single‐point MRD assessment in children with BCP‐ALL treated with the reduced‐intensity protocol ALL‐MB 2008. Data from consecutive MFC–MRD at day 15 and day 36 (end of induction, EOI) were available for 507 children with Philadelphia‐negative BCP‐ALL. They were stratified into standard risk (SR, n = 265), intermediate risk (ImR, n = 211), and high risk (HR, n = 31) according to the initial clinical characteristics defined in the ALL‐MB 2008 protocol. Quantitative (relative to quantitative thresholds) and kinetic (logarithmic reduction) assessments of MFC–MRD at both time points effectively separated patients into three groups with different risk of recurrence. On the other hand, starting with low (for the SR group) and moderate (for the ImR group) induction therapy, a single MFC–MRD measurement at EOI proved sufficient to unequivocally identify patients in whom this therapy is highly effective and distinguish them from those who cannot be successfully treated with such therapy. Therefore, initiating treatment with low or moderate treatment from the start, together with careful consideration of initial clinical risk factors and just one EOI–MFC–MRD measurement is simple, inexpensive, and entirely sufficient for treatment optimization. Furthermore, for a large proportion of patients, this approach allows better adjustment, in particular also reduction of therapy intensity than sequential MRD measurements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBurkitt LymphomaChildHumansNeoplasm, ResidualPrognosisFlow Cytometry

Stichwörter der Autor:innen

acute lymphoblastic leukemiaflow cytometryminimal residual disease

Autor:innen und Institutionen

  • National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
  • Department of Pediatric Oncology Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
  • Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Moscow City Blood Center named after OK Gavrilov, Moscow, Russian Federation.

ORCID-Profile: Alexander Popov, Grigory Tsaur

Zitieren

APA

Popov, A., Henze, G., Roumiantseva, J., Budanov, O., Belevtsev, M., Verzhbitskaya, T., Boyakova, E., Movchan, L., Tsaur, G., Fadeeva, M., Lagoyko, S., Zharikova, L., Miakova, N., Litvinov, D., Khlebnikova, O., Streneva, O., Stolyarova, E., Ponomareva, N., Novichkova, G., …, & Karachunskiy, A. (2023). A simple procedure to identify children with B‐lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single‐point minimal residual disease measurement. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30295

Vancouver

Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, et al. A simple procedure to identify children with B‐lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single‐point minimal residual disease measurement. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30295

BibTeX
@article{Popov2023,
  author = {Popov, Alexander and Henze, Guenter and Roumiantseva, Julia and Budanov, Oleg and Belevtsev, Mikhail and Verzhbitskaya, Tatiana and Boyakova, Elena and Movchan, Liudmila and Tsaur, Grigory and Fadeeva, Maria and Lagoyko, Svetlana and Zharikova, Liudmila and Miakova, Natalia and Litvinov, Dmitry and Khlebnikova, Olga and Streneva, Olga and Stolyarova, Elena and Ponomareva, Natalia and Novichkova, Galina and Fechina, Larisa and Aleinikova, Olga and Karachunskiy, Alexander},
  title = {A simple procedure to identify children with B‐lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single‐point minimal residual disease measurement},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30295}
}
Kostenlos starten →